<a href="https://www.fiercebiotech.com/biotech/fulcrum-scraps-scd-program-considers-options-after-fda-takes-hard-line-safety-risks" hreflang="en">Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks</a>
Fulcrum Therapeutics has discontinued its clinical program for pociredir, a PRC2 inhibitor for sickle cell disease, after the FDA expressed concerns about potential malignancy risks similar to those seen with Ipsen's recently withdrawn drug, Tazverik. The company is now exploring strategic alternatives, including potential mergers or asset sales, as its stock plummeted by 51% following the announcement.
The key insight for a professional in healthtech and biotech is the FDA's stringent stance on PRC2 inhibitors, leading to the discontinuation of Fulcrum Therapeutics' sickle cell disease program due to perceived malignancy risks. This highlights the critical importance of understanding regulatory perspectives and safety profiles, which can significantly impact clinical development and investment decisions. For those tracking health AI and precision medicine, it underscores the need for robust mechanistic differentiation and preclinical data to mitigate regulatory challenges.